The landmark STEP 1 trial provides the most detailed body composition data for semaglutide
Studies show that higher levels are associated with smaller fat cell size and healthier fat distribution patterns
Results from the FLOW trial, which assessed semaglutide (Ozempic, Novo Nordisk) in adults with type 2 diabetes and CKD, were first presented at the European Renal Association Congress and published in The New England Journal of Medicine in May
In these studies, an effect of Gln supplementation on gastric inflammation and cytokine expression was observed 41
Whether its for recovery, reducing inflammation, or improving gut health, the right peptide could be the solution theyve been searching for
Importantly, GLP-1 and glucagon act through structurally related receptors and both peptides exhibit similar amino acid N-terminal sequences, a domain essential for proper interaction with their receptors